Evidence map›Paper›PMID 33080870›Full record

ArticleJournal of personalized medicine2020

Local Disease-Free Survival Rate (LSR) Application to Personalize Radiation Therapy Treatments in Breast Cancer Models.

Gaetano Savoca, Marco Calvaruso, Luigi Minafra, Valentina Bravatà, Francesco Paolo Cammarata, Giuseppina Iacoviello, Boris Abbate, Giovanna Evangelista, Massimiliano Spada, Giusi Irma Forte and 1 more

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gaetano SavocaInstitute of Molecular Bioimaging and Physiology (IBFM-CNR), 90015 Cefalù (PA), Italy.
Marco CalvarusoInstitute of Molecular Bioimaging and Physiology (IBFM-CNR), 90015 Cefalù (PA), Italy.
Luigi MinafraInstitute of Molecular Bioimaging and Physiology (IBFM-CNR), 90015 Cefalù (PA), Italy.
Valentina BravatàInstitute of Molecular Bioimaging and Physiology (IBFM-CNR), 90015 Cefalù (PA), Italy.
Francesco Paolo CammarataInstitute of Molecular Bioimaging and Physiology (IBFM-CNR), 90015 Cefalù (PA), Italy.
Giuseppina IacovielloMedical Physics Department, ARNAS-Civico Hospital, 90100 Palermo, Italy.ORCID 0000-0001-8484-0944
Boris AbbateMedical Physics Department, ARNAS-Civico Hospital, 90100 Palermo, Italy.
Giovanna EvangelistaRadiation Oncology, ARNAS-Civico Hospital, 90100 Palermo, Italy.
Massimiliano SpadaOncology Unit, Fondazione Istituto G. Giglio, 90015 Cefalù (PA), Italy.
Giusi Irma ForteInstitute of Molecular Bioimaging and Physiology (IBFM-CNR), 90015 Cefalù (PA), Italy.
Giorgio RussoInstitute of Molecular Bioimaging and Physiology (IBFM-CNR), 90015 Cefalù (PA), Italy.

Funding

Ministero dello Sviluppo Economico GeSeTON project grant n.489 of 21/02/2018
6 · The paper itself

Abstract

Cancer heterogeneity represents the main issue for defining an effective treatment in clinical practice, and the scientific community is progressively moving towards the development of more personalized therapeutic regimens. Radiotherapy (RT) remains a fundamental therapeutic treatment used for many neoplastic diseases, including breast cancer (BC), where high variability at the clinical and molecular level is known. The aim of this work is to apply the generalized linear quadratic (LQ) model to customize the radiant treatment plan for BC, by extracting some characteristic parameters of intrinsic radiosensitivity that are not generic, but may be exclusive for each cell type. We tested the validity of the generalized LQ model and analyzed the local disease-free survival rate (LSR) for breast RT treatment by using four BC cell cultures (both primary and immortalized), irradiated with clinical X-ray beams. BC cells were chosen on the basis of their receptor profiles, in order to simulate a differential response to RT between triple negative breast and luminal adenocarcinomas. The MCF10A breast epithelial cell line was utilized as a healthy control. We show that an RT plan setup based only on α and β values could be limiting and misleading. Indeed, two other parameters, the doubling time and the clonogens number, are important to finely predict the tumor response to treatment. Our findings could be tested at a preclinical level to confirm their application as a variant of the classical LQ model, to create a more personalized approach for RT planning.

Indexed as

breast cancerLQ modelLSRpersonalized treatmentsradiotherapy

Identifiers

PMID33080870
PMCPMC7712665

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.